Tag: aslan pharmaceuticals

January 30, 2019

ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring

ASLAN Pharmaceuticals (Nasdaq:ASLN,TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, today announced a strategic corporate restructuring...
January 15, 2019

ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI

ASLAN Pharmaceuticals (NASDAQ:ASLN,TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in...
January 14, 2019

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications...
November 8, 2018

ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications...
August 20, 2018

ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia

ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications...
August 10, 2018

ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer

ASLAN Pharmaceuticals (NASDAQ:ASLN) (TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications...